Medytox Establishes US Corporation 'Lubantas' to Support Entry into New Toxin Market

Medytox announced on the 3rd that it has established a local subsidiary, 'Lubantas,' in Irvine, California, USA. This move aims to support the global market entry of the non-animal liquid toxin 'MT10109L,' for which approval was applied to the U.S. Food and Drug Administration (FDA) last month.

Thomas Albright Lubantas, newly appointed CEO
Photo by Medytox

Lubantas, a wholly owned subsidiary of Medytox, will handle local sales and marketing of MT10109L in the U.S., Canada, and other markets, targeting approval next year. Additionally, it plans to advance the market entry of hyaluronic acid (HA) filler 'Neuramis' and dermocosmetic 'Neuraderm' in the future.

The CEO position is held by Thomas Albright, formerly of Allergan. CEO Albright was in charge of global marketing strategy for the aesthetic botulinum toxin (BTX) product 'Botox' and contributed to research and development (R&D) of new therapeutic indications and next-generation biologics.

A Medytox representative stated, "The establishment of Lubantas signifies that Medytox, which has long prepared to become a global company, has completed its strategic planning and entered the full-scale execution phase. We will concentrate all company capabilities on obtaining FDA approval for MT10109L and thoroughly prepare in advance to successfully enter the U.S. market."